Literature DB >> 34735382

Minimally Invasive Compared With Open Hysterectomy in High-Risk Endometrial Cancer.

Blanca Segarra-Vidal1, Giorgia Dinoi, Andres Zorrilla-Vaca, Andrea Mariani, Vladimir Student, Nuria Agustí Garcia, Antonio Llueca Abella, Pedro T Ramirez.   

Abstract

OBJECTIVE: To compare disease-free survival between minimally invasive surgery and open surgery in patients with high-risk endometrial cancer.
METHODS: We conducted a multicentric, propensity-matched study of patients with high-risk endometrial cancer who underwent hysterectomy, bilateral salpingo-oophorectomy, and staging between January 1999 and June 2016 at two centers. High-risk endometrial cancer included grade 3 endometrioid, serous, clear cell, undifferentiated carcinoma or carcinosarcoma with any myometrial invasion. Patients were categorized a priori into two groups based on surgical approach, propensity scores were calculated based on potential confounders and groups were matched 1:1 using nearest neighbor technique. Cox hazard regression analysis and Kaplan-Meier curves evaluated the association of surgical technique with survival.
RESULTS: Of 626 eligible patients, 263 (42%) underwent minimally invasive surgery and 363 (58%) underwent open surgery. In the matched cohort, there were no differences in disease-free survival rates at 5 years between open (53.4% [95% CI 45.6-60.5%]) and minimally invasive surgery (54.6% [95% CI 46.6-61.8]; P=.82). Minimally invasive surgery was not associated with worse disease-free survival (hazard ratio [HR] 0.85, 95% CI 0.63-1.16; P=.30), overall survival (HR 1.04, 95% CI 0.73-1.48, P=.81), or recurrence rate (HR 0.99; 95% CI 0.69-1.44; P=.99) compared with open surgery. Use of uterine manipulator was not associated with worse disease-free survival (HR 1.01, 95% CI 0.65-1.58, P=.96), overall survival (HR 1.18, 95% CI 0.71-1.96, P=.53), or recurrence rate (HR 1.12, 95% CI 0.67-1.87; P=.66).
CONCLUSION: There was no difference in oncologic outcomes comparing minimally invasive and open surgery among patients with high-risk endometrial cancer.
Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34735382     DOI: 10.1097/AOG.0000000000004606

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Prospective Multicenter Trial Assessing the Impact of Positive Peritoneal Cytology Conversion on Oncological Outcome in Patients with Endometrial Cancer Undergoing Minimally Invasive Surgery with the use of an Intrauterine Manipulator : Positive Peritoneal Cytology Conversion and Its Association with Oncological Outcome in Endometrial Cancer.

Authors:  Franziska Siegenthaler; Silke Johann; Sara Imboden; Nicolas Samartzis; Haiyan Ledermann-Liu; Dimitri Sarlos; Markus Eberhard; Michael D Mueller
Journal:  Ann Surg Oncol       Date:  2022-09-04       Impact factor: 4.339

2.  Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.

Authors:  William A Zammarrelli; Michelle Greenman; Eric Rios-Doria; Katie Miller; Vance Broach; Jennifer J Mueller; Emeline Aviki; Kaled M Alektiar; Robert A Soslow; Lora H Ellenson; Vicky Makker; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2022-02-26       Impact factor: 5.304

3.  Survival Analysis in Endometrial Carcinomas by Type of Surgical Approach: A Matched-Pair Study.

Authors:  Pluvio J Coronado; Agnieszka Rychlik; Laura Baquedano; Virginia García-Pineda; Maria A Martínez-Maestre; Denis Querleu; Ignacio Zapardiel
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

4.  Survival after laparoscopy versus laparotomy for apparent early-stage uterine clear cell carcinoma: Results of a large multicenter cohort study.

Authors:  Chengyu Shui; Lin Ran; Yong Tian; Li Qin; Xin Gu; Hui Xu; Cui Hu; Lin-Lin Zhang; You Xu; Chen Cheng; Wu Huan
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.